Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Company Deals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Fineline Cube Dec 13, 2025
Company Deals

Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Fineline Cube Dec 13, 2025
Company Drug

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer

Fineline Cube Dec 13, 2025
Company Drug

Eli Lilly’s Efsitora Meets Key Endpoints in Phase III Trials for Type 2 Diabetes

Fineline Cube Jun 23, 2025

US major Eli Lilly and Company (NYSE: LLY) presented detailed results from the Phase III...

Company Drug

Johnson & Johnson’s Imbruvica Secures CHMP Recommendation for Expanded MCL Use

Fineline Cube Jun 23, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products...

Company Drug

Bayer’s Nubeqa Receives Positive CHMP Opinion for mHSPC Treatment

Fineline Cube Jun 23, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced last week that the European Medicines Agency...

Company Deals

Boao Lecheng Partners with China National Center for Neurological Diseases to Establish Translational Center

Fineline Cube Jun 23, 2025

The Boao Lecheng International Medical Tourism Pilot Zone Administration announced last week a strategic cooperation...

Company Drug

Sichuan Huiyu’s CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval

Fineline Cube Jun 23, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) announced that it has received clinical trial...

Company Drug

Changshan Biochemical Receives NMPA Clearance for Albenatide in Weight Loss Trials

Fineline Cube Jun 23, 2025

China’s Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) announced that it has received...

Company Drug

ImmuneOnco Receives NMPA Approval for IMC-003/IMM72 in Pulmonary Arterial Hypertension Trial

Fineline Cube Jun 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced that it has received clinical trial...

Company Deals

United Imaging Intelligence Closes RMB 1B Series A Round to Boost AI in Healthcare

Fineline Cube Jun 23, 2025

United Imaging Intelligence, the AI-focused subsidiary of Shanghai United Imaging Healthcare Co., Ltd., reportedly secured...

Company Medical Device

MGI Tech’s DNBSEQ-T1+ Gains CE IVDR Certification for EU Market Entry

Fineline Cube Jun 23, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) announced that its latest mid-throughput...

Company Deals

Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million

Fineline Cube Jun 23, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake...

Company Drug

Simcere Pharma’s Quviviq Receives NMPA Approval for Insomnia Treatment

Fineline Cube Jun 23, 2025

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) revealed that its marketing approval filing for Quviviq...

Company Drug

Sanofi and Regeneron Win FDA Approval for Dupixent in Bullous Pemphigoid Treatment

Fineline Cube Jun 23, 2025

France major Sanofi (NASDAQ: SNY) and US-based biopharma Regeneron (NASDAQ: REGN) announced that Dupixent (dupilumab)...

Company Drug

Zai Lab’s Partner argenx Secures EU Approval for Vygart in CIDP Treatment

Fineline Cube Jun 23, 2025

China-based Zai Lab Limited’s (NASDAQ: ZLAB, HKG: 9688) Dutch partner argenx SE (NASDAQ: ARGX) announced...

Company Deals

Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager

Fineline Cube Jun 23, 2025

China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...

Company Drug

CanSino Biologics’ PCV13i Vaccine Gains NMPA Approval

Fineline Cube Jun 23, 2025

China-based CanSino Biologics Inc., (HKG: 6185) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment

Fineline Cube Jun 20, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...

Company Drug

Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC

Fineline Cube Jun 20, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its...

Company Drug

Shanghai Pharmaceuticals Receives Thai FDA Approval for Pregabalin Capsules

Fineline Cube Jun 20, 2025

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that it has...

Company Drug

Wantai Biological Launches Phase III Trial for VZV-7D Varicella Vaccine

Fineline Cube Jun 20, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation of...

Company Drug

MSD Initiates IDeate-Prostate01 Phase III Trial of Ifinatamab Deruxtecan for mCRPC

Fineline Cube Jun 20, 2025

Merck, Sharp & Dohme (MSD, NYSE: MRK) this week announced the first patient dosing in...

Posts pagination

1 … 70 71 72 … 596

Recent updates

  • InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor
  • Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
  • GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
  • B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
  • OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.